The European Medicines Agency has been formally notified by Merck KGaA of its decision to withdraw its application for an extension of the therapeutic indication for the centrally authorised medicine Erbitux (cetuximab), 5-mg/ml solution for infusion.
Go to Source

This entry was posted on Saturday, October 13th, 2012 at 11:30 pm and is filed under European Medicines Agency. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.